The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
4198627
Approach for scaling down pCO2 from clinical process to Ambr® 250 scale | Poster Board #189
Date
March 25, 2025
Bioreactor scale down models (SDM) are necessary for process development and process characterization. Ambr® 250 fed-batch bioreactors have demonstrated large-scale reproducibility and significant process development time savings when used as SDM for GMP manufacturing. A late-stage IgG1 mAb produced in a CHO cell line has sensitivity to pCO2 concentrations and pH levels during both the growth and production phase that result in changes to process performance and critical quality attributes. These critical process parameters (CPP) are affected by both scale-independent factors (media pH, buffering capacity, and pH control setpoints) and scale-dependent process parameters (agitation, stir speed, and sparger design). Scale-independent process parameters can directly align with the large scale bioreactor control strategy. Scale-dependent parameters are generally chosen through scaling parameters such as maintaining power-to-volume (P/V), gas flowrate per unit volume (VVM), or the oxygen gas transfer coefficient (kLa) which are dominated by agitation and sparged gas flowrates. The main factors chosen in the study for controlling pH and pCO2 are agitation, air sparge, and CO2 gas flow rates in both open pipe sparger and the headspace. During the growth phase, air sparge has the greatest effect on pCO2 levels. During the production phase, VVM was dominated by the oxygen sparge rate as this cell line has a high oxygen uptake rate (OUR). The high VVM in the production phase decreased the pCO2 level from the target. Increasing the agitation to improve the oxygen gas transfer decreased the oxygen gas flowrate demands and subsequently increased the pCO2. Additional CO2 sparge has a greater effect than CO2 headspace gassing at increasing the pCO2. This work provided process parameter levers for modifying pCO2/pH at the Ambr® 250 scale which can significantly help develop more representative scale down models for more complex modalities and improve development timelines.
Biologic process intensification strategies are beneficial in the field of therapeutic protein production for higher productivity, lower cost of goods, and improved facility utilization…
Fc-fusion proteins present challenges in early upstream process development that require additional considerations outside of a monoclonal antibody platform because of their unique and complex product quality profile…
Perfusion cell culture is an attractive option to meet the growing demand for biologics because it can be significantly more productive compared to fed-batch processing…
Ultra-high cell density perfusion cultures for integrated continuous manufacturing are becoming increasingly attractive for biologics processes. Such processes enable a flexible manufacturing footprint, increased productivities, and improved cost of goods…